PharmaGap raises $1 million

PharmaGap Inc. sells 5.6 million equity PharmaGap-logo.JPGsecurities, raising over $1 million, which it will use for additional testing of its lead cancer drug PhGalpha1 and general working purposes. Consisting of one common share and one purchase warrant, the units sold for 12.5 cents each in two offerings, with two million units picked up by investors on May 4 and another 3.6 million on June 4. PharmaGap announced in early may that PhGalpha1 had shown in initial tests to improve the effectiveness of a commonly used chemotherapeutic drug in killing cancer cells by approximately 50%.

Submit a comment

Please leave your name, which will be used to sign your submission to the SCANsite. Thanks for contributing your thoughts. Come back again. Tony Patterson, Editor & CEO.

© 2006 - 2009 SCAN
INTEGRITY INTELLIGENCE INFORMATION
Site by Citadel Rock
SCAN